Acetate supplementation as a means of inducing glioblastoma stem-like cell growth arrest

Journal of Cellular Physiology

Volumn 230, Issue 8, 2015, Pages 1929-1943

  Long, Patrick M ^a   Tighe, Scott W ^a   Driscoll, Heather E ^b   Fortner, Karen A ^a   Viapiano, Mariano S ^c   Jaworski, Diane M ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NORWICH UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ASPARTOACYLASE; HERMES ANTIGEN; N ACETYLASPARTIC ACID; TRIACETIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MIDDLE AGED; MOUSE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; SUPPLEMENTATION; ANIMAL; CANCER STEM CELL; CELL CULTURE; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MURINAE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTES; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; NEOPLASTIC STEM CELLS; NEURAL STEM CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIACETIN;

EID: 84928382633     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24927     Document Type: Article

References (89)

1. Abe A, Saeki K, Yasunaga T, Wakabayashi T. 2000. Acetylation at the N-terminus of actin strengthens weak interaction between actin and myosin. Biochem Biophys Res Commun 268:14-19.
2. Anderson KA, Hirschey MD. 2012. Mitochondrial protein acetylation regulates metabolism. Essays Biochem 52:23-35.
3. Ariyannur PS, Moffett JR, Madhavarao CN, Arun P, Vishnu N, Jacobowitz DM, Hallows WC, Denu JM, Namboodiri AM. 2010. Nuclear-cytoplasmic localization of acetyl coenzyme a synthetase-1 in the rat brain. J Comp Neurol 518:2952-2977.
4. Ariyannur PS, Arun P, Barry ES, Andrews-Shigaki B, Bosomtwi A, Tang H, Selwyn R, Grunberg NE, Moffett JR, Namboodiri AM. 2013. Do reductions in brain N-acetylaspartate levels contribute to the etiology of some neuropsychiatric disorders. J Neurosci Res 91:934-942.
5. Arun P, Ariyannur PS, Moffett JR, Xing G, Hamilton K, Grunberg NE, Ives JA, Namboodiri AM. 2010a. Metabolic acetate therapy for the treatment of traumatic brain injury. J Neurotrauma 27:293-298.
6. Arun P, Madhavarao CN, Moffett JR, Hamilton K, Grunberg NE, Ariyannur P, Gahl WA, Anikster Y, Mog S, Hallows WC, Denu JM, Namboodiri AM. 2010b. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease. J Inherit Metab Dis 33:195-210.
7. Bánréti A, Sass M, Graba Y. 2013. The emerging role of acetylation in the regulation of autophagy. Autophagy 9:819-829.
8. Bhatt DP, Houdek HM, Watt JA, Rosenberger TA. 2013. Acetate supplementation increases brain phosphocreatine and reduces AMP levels with no effect on mitochondrial biogenesis. Neurochem Int 62:296-305.
9. Brissette CA, Houdek HM, Floden AM, Rosenberger TA. 2012. Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis. J Neuroinflammation 9:249.
10. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A. 2005. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113-121.
11. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA. 2011. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108:7950-7955.
12. Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S, Eschrich S, Qu X, Forsyth P, Gillies R. 2012. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res 72:5878-5888.
13. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834-840.
14. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross J, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K. 2010. A multigene predictor of outcome in glioblastoma. Neuro Oncol 12:49-57.
15. Consalvi S, Saccone V, Giordani L, Minetti G, Mozzetta C, Puri PL. 2011. Histone deacetylase inhibitors in the treatment of muscular dystrophies: Epigenetic drugs for genetic diseases. Mol Med 17:457-465.
16. Dawson MR, Polito A, Levine JM, Reynolds R. 2003. NG2-expressing glial progenitor cells: An abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci 24:476-488.
17. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39.
18. Faraco G, Cavone L, Chiarugi A. 2011. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med 17:442-447.
19. Fiume MZ, Panel CIRE. 2003. Final report on the safety assessment of triacetin. Int J Toxicol 22:1-10.
20. Forte GM, Pool MR, Stirling CJ. 2011. N-terminal acetylation inhibits protein targeting to the endoplasmic reticulum. PLoS Biol 9:e1001073.
21. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer N, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. 2005. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400.
22. Fujino T, Kondo J, Ishikawa M, Morikawa K, Yamamoto TT. 2001. Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. J Biol Chem 276:11420-11426.
23. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca EA, Lawler S. 2008. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 68:9125-9130.
24. Goldberg RP, Brunengraber H. 1980. Contributions of cytosolic and mitochondrial acetyl-CoA syntheses to the activation of lipogenic acetate in rat liver. Adv Exp Med Biol 132:413-418.
25. Gryder BE, Sodji QH, Oyelere AK. 2012. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 4:505-524.
26. Gupta PB, Fillmore CM, Jiang G, Shapira S, Tao K, Kuperwasser C, Lander ES. 2011. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146:633-644.
27. Hallows WC, Lee S, Denu JM. 2006. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA 103:10230-10235.
28. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. 2005. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311-321.
29. Hershfield JR, Madhavarao CN, Moffett JR, Benjamins JA, Garbern JY, Namboodiri A. 2006. Aspartoacylase is a regulated nuclear-cytoplasmic enzyme. FASEB J 20:2139-2141.
30. Hwang CS, Shemorry A, Varshavsky A. 2010. N-terminal acetylation of cellular proteins creates specific degradation signals. Science 327:973-977.
31. Jaworski DM, Pérez-Martínez L. 2006. Tissue inhibitor of metalloproteinase-2 (TIMP-2) expression is regulated by multiple neural differentiation signals. J Neurochem 98:234-247.
32. Jiang Y, Boije M, Westermark B, Uhrbom L. 2011. PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation. Neoplasia 13:492-503.
33. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, de Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I. 2011. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 6:24217.
34. Kaul R, Casanova J, Johnson AB, Tang P, Matalon R. 1991. Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 56:129-135.
35. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, Cheng T, Kho Y, Xiao H, Xiao L, Grishin NV, White M, Yang XJ, Zhao Y. 2006. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23:607-618.
36. Koch MW, Metz LM, Kovalchuk O. 2013. Epigenetic changes in patients with multiple sclerosis. Nat Rev Neurol 9:35-43.
37. Konsoula Z, Barile FA. 2012. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders. J Pharmacol Toxicol Methods 66:215-220.
38. Koppenol WH, Bounds PL, Dang CV. 2011. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11:325-337.
39. Li X, Corsa CA, Pan PW, Wu L, Ferguson D, Yu X, Min J, Dou Y. 2010. MOF and H4 K16 acetylation play important roles in DNA damage repair by modulating recruitment of DNA damage repair protein Mdc1. Mol Cell Biol 30:5335-5347.
40. Lin R, Tao R, Gao X, Li T, Zhou X, Guan KL, Xiong Y, Lei QY. 2013. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol Cell 51:506-518.
41. Lluri G, Langlois GD, Soloway PD, Jaworski DM. 2008. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates myogenesis and b1 integrin expression in vitro. Exp Cell Res 314:11-24.
42. Long PM, Moffett JR, Namboodiri AMA, Viapiano MS, Lawler SE, Jaworski DM. 2013a. N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells. J Biol Chem 288:26188-26200.
43. Long PM, Tighe SW, Driscoll HE, Moffett JR, Namboodiri AMA, Viapiano MS, Lawler SE, Jaworski DM. 2013b. Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells. PLoS One 8:80714.
44. Madhavarao CN, Arun P, Anikster Y, Mog SR, Staretz-Chacham O, Moffett JR, Grunberg NE, Gahl WA, Namboodiri AM. 2009. Glyceryl triacetate for Canavan disease: a low-dose trial in infants and evaluation of a higher dose for toxicity in the tremor rat model. J Inherit Metab Dis 32:640-650.
45. Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, Wang M, Hu B, Cheng SY, Sobol RW, Nakano I. 2013. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 110:8644-8649.
46. Marin-Husstege M, Muggironi M, Liu A, Casaccia-Bonnefil P. 2002. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J Neurosci 22:10333-10345.
47. Marks PA, Richon VM, Rifkind RA. 2000. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216.
48. Marouco D, Garabadgiu AV, Melino G, Barlev NA. 2013. Lysine-specific modifications of p53: A matter of life and death. Oncotarget 4:1556-1571.
49. Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA. 2005. Progress toward acetate supplementation therapy for Canavan disease: Glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther 315:297-303.
50. McBride DQ, Miller BL, Nikas DL, Buchthal S, Chang L, Chiang F, Booth RA. 1995. Analysis of brain tumors using 1H magnetic resonance spectroscopy. Surg Neurol 44:137-144.
51. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, Petruk KC. 2010. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34.
52. Michelakis ED, Webster L, Mackey JR. 2008. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 99:989-994.
53. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM. 2007. N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology. Prog Neurobiol 81:89-131.
54. Moffett JR, Arun P, Ariyannur PS, Garbern J, Jacobowitz DM, Namboodiri AM. 2011. Extensive aspartoacylase expression in the rat central nervous system. Glia 59:1414-1434.
55. Moffett JR, Arun P, Ariyannur PS, Namboodiri AM. 2013. N-Acetylaspartate reductions in brain injury: Impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation. Front Neuroenergetics 5:11.
56. Myzak MC, Ho E, Dashwood RH. 2006. Dietary agents as histone deacetylase inhibitors. Mol Carcinog 45:443-446.
57. Newman JC, He W, Verdin E. 2012. Mitochondrial protein acylation and intermediary metabolism: Regulation by sirtuins and implications for metabolic disease. J Biol Chem 287:42436-42443.
58. Ohshiro K, Rayala SK, Wigerup C, Pakala SB, Natha RS, Gururaj AE, Molli PR, Månsson SS, Ramezani A, Hawley RG, Landberg G, Lee NH, Kumar R. 2010. Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Rep 11:691-697.
59. Persson B, Flinta C, von Heijne G, Jörnvall H. 1985. Structures of N-terminally acetylated proteins. Eur J Biochem 152:523-527.
60. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
61. Pisano C, Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F. 2010. Metabolic approach to the enhancement of antitumor effect of chemotherapy: A key role of acetyl-L-carnitine. Clin Cancer Res 16:3944-3953.
62. Reisenauer CJ, Bhatt DP, Mitteness DJ, Slanczka ER, Gienger HM, Watt JA, Rosenberger TA. 2011. Acetate supplementation attenuates lipopolysaccharide-induced neuroinflammation. J Neurochem 117:264-274.
63. Rigotti DJ, Kirov II, Djavadi B, Perr yN, Babb JS, Gonen O. 2011. Longitudinal whole-brain N-acetylaspartate concentration in healthy adults. AJNR Am J Neuroradiol 32:1011-1015.
64. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, Botrugno OA, Parazzoli D, Oldani A, Minucci S, Foiani M. 2011. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471:74-79.
65. Roesler R, Brunetto AT, Abujamra AL, de Farias CB, Brunetto AL, Schwartsmann G. 2010. Current and emerging molecular targets in glioma. Expert Rev Anticancer Ther 10:1735-1751.
66. Schweizer S, Meisel A, Märschenz S. 2013. Epigenetic mechanisms in cerebral ischemia. J Cereb Blood Flow Metab 33:1335-1346.
67. Scott DC, Monda JK, Bennett EJ, Harper JW, Schulman BA. 2011. N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex. Science 334:674-678.
68. Segel R, Anikster Y, Zevin S, Steinberg A, Gahl WA, Fisher D, Staretz-Chacham O, Zimran A, Altarescu G. 2011. A safety trial of high dose glyceryl triacetate for Canavan disease. Mol Genet Metab 103:203-206.
69. Seidel C, Schnekenburger M, Dicato M, Diederich M. 2012. Histone deacetylase modulators provided by Mother Nature. Genes Nutr 7:357-367.
70. Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK. 2009. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174:1619-1628.
71. Shein NA, Shohami E. 2011. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol Med 17:448-456.
72. Shimada IS, LeComte MD, Granger J, Quinlan NJ, Spees JL. 2012. Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from cortical peri-infarct tissues after stroke. J Neurosci 32:7926-7940.
73. Shubassi G, Robert T, Vanoli F, Minucci S, Foiani M. 2012. Acetylation: A novel link between double-strand break repair and autophagy. Cancer Res 72:1332-1335.
74. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401.
75. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. 2010. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 10:935-954.
76. Soliman ML, Rosenberger TA. 2011. Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression. Mol Cell Biochem 352:173-180.
77. Soliman ML, Smith MD, Houdek HM, Rosenberger TA. 2012. Acetate supplementation modulates brain histone acetylation and decreases interleukin-1β expression in a rat model of neuroinflammation. J Neuroinflammation 9:51.
78. Starai VJ, Celic I, Cole RN, Boeke JD, Escalante-Semerena JC. 2002. Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science 298:2390-2392.
79. Starheim KK, Gevaert K, Arnesen T. 2012. Protein N-terminal acetyltransferases: When the start matters. Trends Biochem Sci 37:152-161.
80. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Groups EOfRaToCBTaR, Group NCIoCCT. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
81. Takahashi H, McCaffery JM, Irizarry RA, Boeke JD. 2006. Nucleocytosolic acetyl-coenzyme a synthetase is required for histone acetylation and global transcription. Mol Cell 23:207-217.
82. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. 2008. Acetylation is indispensable for p53 activation. Cell 133:612-626.
83. Tsen AR, Long PM, Driscoll HE, Davies MT, Teasdale BA, Penar PL, Pendlebury WW, Spees JL, Lawler SE, Viapiano MS, Jaworski DM. 2014. Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma. Int J Cancer 134:1300-1310.
84. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Network CGAR. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
85. Wang Q, Zhang Y, Yang C, Xiong H, Lin Y, Yao J, Li H, Xie L, Zhao W, Yao Y, Ning ZB, Zeng R, Xiong Y, Guan KL, Zhao S, Zhao GP. 2010. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 327:1004-1007.
86. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. 2009. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324:1076-1080.
87. Xie J, Wang BS, Yu DH, Lu Q, Ma J, Qi H, Fang C, Chen HZ. 2011. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. Int J Oncol 38:409-417.
88. Xu W, Li Y, Liu C, Zhao S. 2013. Protein lysine acetylation guards metabolic homeostasis to fight against cancer. Oncogene. doi: 10.1038/onc.2013.163
89. Yang XJ, Seto E. 2008. Lysine acetylation: Codified crosstalk with other posttranslational modifications. Mol Cell 31:449-461.